In a groundbreaking move for women’s health, the name polycystic ovary syndrome (PCOS) has officially transitioned to polyendocrine metabolic ovarian syndrome (PMOS). This change, hailed as one of the most extensive global engagement processes ever undertaken for a health condition, aims to better reflect the complexities of the condition and enhance awareness, diagnosis, and treatment for the millions affected worldwide.
Understanding the Change
The previous designation, PCOS, has long been a source of confusion and misrepresentation. Contrary to the implication of its name, individuals diagnosed with this condition do not necessarily present with an increase in ovarian cysts. Instead, the primary feature is the presence of fluid-filled sacs around partially developed eggs, a disruption caused by hormonal imbalances. This misunderstanding has led to underdiagnosis and inadequate treatment, as the broader implications of the condition remained overlooked.
In a statement from Monash University, Professor Helena Teede, who spearheaded the name change initiative, explained, “PMOS builds on previous understandings, truly reflecting the diverse and multifaceted features of this condition.” The shift to PMOS aims to acknowledge the significant polyendocrine disturbances in insulin, androgens, and ovarian hormones, which profoundly impact the lives of those affected.
The Voices Behind the Change
The decision to rename this condition has been met with enthusiasm by those who have dedicated years to raising awareness about PMOS. Robyn Vettese, chair of the PMOS Patient Advisory Council in Alberta, expressed hope that the new terminology will help dismantle the stigma surrounding the condition, particularly regarding weight gain and mental health challenges like anxiety and depression. She stated, “We want all patients, whose symptoms can vary widely, to receive the understanding and support they deserve for their long-term health.”
Over the past decade, a committed team of advocates and researchers has worked tirelessly to ensure the voices of patients were central to this process. A survey conducted in 2025 revealed overwhelming support for the name change, with 85.6% of patients and 76.1% of healthcare professionals in favour. This backing was crucial in the transition, which involved input from over 22,000 individuals, including 56 leading academic and clinical organisations.
A Future Focused on Education and Research
Looking ahead, the rebranding to PMOS is seen not just as a change in nomenclature but as a rallying cry for improved education and research surrounding the condition. Vettese is keen to engage care providers, encouraging them to embrace a holistic approach to health that encompasses the numerous aspects of PMOS.
Dr. Jamie Benham, an endocrinologist at the University of Calgary and a key contributor to the name change, echoed these sentiments. She highlighted the importance of raising awareness about PMOS and ensuring that research efforts align with the needs of those affected. The transition period, anticipated to last three years, is expected to foster an increase in PMOS care across various medical fields, including endocrinology and gynecology.
Why it Matters
The renaming of PCOS to PMOS is a pivotal moment in women’s health, representing a collective effort to bring attention to a condition that has historically been misunderstood and mismanaged. By recognising the broader metabolic implications of PMOS, this change promises to enhance the quality of care for millions of women worldwide. It signifies a shift towards a more inclusive and informed healthcare landscape, where the experiences and voices of those living with PMOS are acknowledged and prioritised. As awareness grows and research expands, there is hope for substantial improvements in treatment and support, ultimately leading to healthier lives for those impacted by this complex condition.
